Safety and Tolerability Of An Intravenously Administered Alpha1-Proteinase Inhibitor (A1PI) At An Increased Infusion Rate: A Randomized, Rate Control, Placebo-Masked, Crossover Study In Healthy Adults

Trial Profile

Safety and Tolerability Of An Intravenously Administered Alpha1-Proteinase Inhibitor (A1PI) At An Increased Infusion Rate: A Randomized, Rate Control, Placebo-Masked, Crossover Study In Healthy Adults

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2014

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Alpha 1-antitrypsin deficiency; Bronchiectasis; Cystic fibrosis; Emphysema; Graft-versus-host disease; Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Apr 2014 New trial record
    • 04 Mar 2014 Results presented at the 70th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top